ABSTRACT
Stevia rebaudiana Bertoni is a native plant to Paraguay. The extracts have been used as a famous sweetening agent, and the bioactive components derived from stevia possess a broad spectrum of therapeutical potential for various illnesses. Among its medicinal benefits are anti-hypertensive, anti-tumorigenic, anti-diabetic, and anti-hyperlipidemia. Statins (3-hydro-3-methylglutaryl-coenzyme A reductase inhibitor) are a class of drugs used to treat atherosclerosis. Statins are explicitly targeting the HMG-CoA reductase, an enzyme in the rate-limiting step of cholesterol biosynthesis. Despite being widely used in regulating plasma cholesterol levels, the adverse effects of the drug are a significant concern among clinicians and patients. Hence, steviol glycosides derived from stevia have been proposed as an alternative in replacing statins. Diterpene glycosides from stevia, such as stevioside and rebaudioside A have been evaluated for their efficacy in alleviating cholesterol levels. These glycosides are a potential candidate in treating and preventing atherosclerosis provoked by circulating lipid retention in the sub-endothelial lining of the artery. The present review is an effort to integrate the pathogenesis of atherosclerosis, involvement of lipid droplets biogenesis and its associated proteins in atherogenesis, current approaches to treat atherosclerosis, and pharmacological potential of stevia in treating the disease.
Subject(s)
Atherosclerosis/prevention & control , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/prevention & control , Dyslipidemias/drug therapy , Hypolipidemic Agents/therapeutic use , Plant Extracts/therapeutic use , Stevia , Animals , Atherosclerosis/diagnosis , Atherosclerosis/epidemiology , Biomarkers/blood , Cardiovascular Agents/adverse effects , Cardiovascular Agents/isolation & purification , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Dyslipidemias/diagnosis , Dyslipidemias/epidemiology , Heart Disease Risk Factors , Humans , Hypolipidemic Agents/adverse effects , Hypolipidemic Agents/isolation & purification , Lipid Droplets/drug effects , Lipid Droplets/metabolism , Lipids/blood , Plant Extracts/adverse effects , Plant Extracts/isolation & purification , Risk Assessment , Stevia/chemistry , Treatment OutcomeABSTRACT
ABSTRACT: Panax notoginseng saponins (PNS) are commonly used in the treatment of cardiovascular diseases. Whether PNS can protect myocardial ischemia-reperfusion injury by regulating the forkhead box O3a hypoxia-inducible factor-1 alpha (FOXO3a/HIF-1α) cell signaling pathway remains unclear. The purpose of this study was to investigate the protective effect of PNS on H9c2 cardiomyocytes through the FOXO3a/HIF-1α cell signaling pathway. Hypoxia and reoxygenation of H9C2 cells were used to mimic MIRI in vitro, and the cells were treated with PNS, 2-methoxyestradiol (2ME2), and LY294002." Cell proliferation, lactate dehydrogenase, and malonaldehyde were used to evaluate the degree of cell injury. The level of reactive oxygen species was detected with a fluorescence microscope. The apoptosis rate was detected by flow cytometry. The expression of autophagy-related proteins and apoptosis-related proteins was detected by western blot assay. PNS could reduce H9c2 hypoxia-reoxygenation injury by promoting autophagy and inhibiting apoptosis through the HIF-1α/FOXO3a cell signaling pathway. Furthermore, the protective effects of PNS were abolished by HIF-1α inhibitor 2ME2 and PI3K/Akt inhibitor LY294002. PNS could reduce H9c2 hypoxia-reoxygenation injury by promoting autophagy and inhibiting apoptosis through the HIF-1α/FOXO3a cell signaling pathway.
Subject(s)
Cardiovascular Agents/pharmacology , Forkhead Box Protein O3/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Myocardial Reperfusion Injury/prevention & control , Myocytes, Cardiac/drug effects , Panax notoginseng , Plant Extracts/pharmacology , Saponins/pharmacology , Animals , Apoptosis/drug effects , Autophagy/drug effects , Cardiovascular Agents/isolation & purification , Cell Line , Membrane Proteins/metabolism , Mitochondrial Proteins/metabolism , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Panax notoginseng/chemistry , Phosphatidylinositol 3-Kinase/metabolism , Plant Extracts/isolation & purification , Proto-Oncogene Proteins c-akt/metabolism , Rats , Reactive Oxygen Species/metabolism , Saponins/isolation & purification , Signal TransductionABSTRACT
The use of medicinal plants as a therapy alternative is old as human existence itself. Nowadays, the search for effective molecules for chronic diseases treatments has increased. The cardiometabolic disorders still the main cause of death worldwide and plants may offer potential pharmacological innovative approaches to treat and prevent diseases. In the range of plant molecules are inserted the terpenes, which constituent essential elements with several pharmacological characteristics and applications, including cardiovascular and metabolic properties. Thus, the aim of the present review is to update the terpenes use on chronic disorders such as obesity, diabetes, hypertension and vascular conditions. The review includes a brief terpenes description based on the scientific literature in addition to data collected from secondary sources such as books and conference proceedings. We concluded that terpenes could act as adjuvant or main alternative treatment (when started earlier) to improve cardiometabolic diseases, contributing to reduce side effects of conventional drugs, in addition to preserving ethnopharmacological knowledge.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Atherosclerosis/drug therapy , Cardiovascular Agents/therapeutic use , Diabetes Mellitus/drug therapy , Hypertension/drug therapy , Obesity/drug therapy , Terpenes/therapeutic use , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/classification , Anti-Inflammatory Agents/isolation & purification , Atherosclerosis/metabolism , Atherosclerosis/pathology , Cardiovascular Agents/chemistry , Cardiovascular Agents/classification , Cardiovascular Agents/isolation & purification , Chemotherapy, Adjuvant/methods , Diabetes Mellitus/metabolism , Diabetes Mellitus/pathology , Disease Models, Animal , Ethnopharmacology/methods , Humans , Hypertension/metabolism , Hypertension/pathology , Obesity/metabolism , Obesity/pathology , Plant Extracts/chemistry , Plants, Medicinal , Stereoisomerism , Terpenes/chemistry , Terpenes/classification , Terpenes/isolation & purificationABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Many studies have shown the beneficial effects of aconite water-soluble alkaloid extract (AWA) in experimental models of heart disease, which have been ascribed to the presence of aconine, hypaconine, talatisamine, fuziline, neoline, and songorine. This study evaluated the effects of a chemically characterized AWA by chemical content, evaluated its effects in suprarenal abdominal aortic coarctation surgery (AAC)-induced chronic heart failure (CHF) in rats, and revealed the underlying mechanisms of action by proteomics. METHODS: Rats were distributed into different groups: sham, model, and AWA-treated groups (10, 20, and 40 mg/kg/day). Sham rats received surgery without AAC, whereas model rats an AWA-treated groups underwent AAC surgery. after 8 weeks, the treatment group was fed AWA for 4 weeks, and body weight was assessed weekly. At the end of the treatment, heart function was tested by echocardiography. AAC-induced chronic heart failure, including myocardial fibrosis, cardiomyocyte hypertrophy, and apoptosis, was evaluated in heart tissue and plasma by RT-qPCR, ELISA, hematoxylin and eosin (H&E) staining, Masson's trichrome staining, TUNEL staining, and immunofluorescence staining of α-SMA, Col â , and Col â ¢. Then, a proteomics approach was used to explore the underlying mechanisms of action of AWA in chronic heart failure. RESULTS: AWA administration reduced body weight gain, myocardial fibrosis, cardiomyocyte hypertrophy, and apoptosis, and rats showed improvement in cardiac function compared to model group. The extract significantly ameliorated the AAC-induced altered expression of heart failure markers such as ANP, NT-proBNP, and ß-MHC, as well as fibrosis, hypertrophy markers MMP-2 and MMP-9, and other heart failure-related factors including plasma levels of TNF-α and IL-6. Furthermore, the extract reduced the protein expression of α-SMA, Col â , and Col â ¢ in the left ventricular (LV), thus inhibiting the LV remodeling associated with CHF. In addition, proteomics characterization of differentially expressed proteins showed that AWA administration inhibited left ventricular remodeling in CHF rats via a calcium signaling pathway, and reversed the expression of RyR2 and SERCA2a. CONCLUSIONS: AWA extract exerts beneficial effects in an AAC-induced CHF model in rats, which was associated with an improvement in LV function, hypertrophy, fibrosis, and apoptotic status. These effects may be related to the regulation of calcium signaling by the altered expression of RyR2 and SERCA2a.
Subject(s)
Aconitum , Calcium Signaling/drug effects , Cardiovascular Agents/pharmacology , Heart Failure/drug therapy , Myocytes, Cardiac/drug effects , Plant Extracts/pharmacology , Aconitum/chemistry , Animals , Apoptosis/drug effects , Cardiovascular Agents/isolation & purification , Chronic Disease , Disease Models, Animal , Fibrosis , Heart Failure/metabolism , Heart Failure/pathology , Heart Failure/physiopathology , Hypertrophy, Left Ventricular/drug therapy , Hypertrophy, Left Ventricular/metabolism , Hypertrophy, Left Ventricular/pathology , Hypertrophy, Left Ventricular/physiopathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Plant Extracts/isolation & purification , Rats, Sprague-Dawley , Ryanodine Receptor Calcium Release Channel/metabolism , Sarcoplasmic Reticulum Calcium-Transporting ATPases/metabolism , Solubility , Solvents/chemistry , Ventricular Dysfunction, Left/drug therapy , Ventricular Dysfunction, Left/metabolism , Ventricular Dysfunction, Left/pathology , Ventricular Dysfunction, Left/physiopathology , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Water/chemistryABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: As the largest genus of Gentianaceae family, the Gentiana genus harbors over 400 species, widely distributed in the alpine areas of temperate regions worldwide. Plants from Gentiana genus are traditionally used to treat a wide variety of diseases including easing pain dispelling rheumatism, and treating liver jaundice, chronic pharyngitis and arthritis in China since ancient times. In this review, a systematic and constructive overview of the traditional uses, phytochemistry, molecular mechanisms, toxicology and pharmacological activities of the researched species of genus Gentiana is provided. MATERIALS AND METHODS: The used information in this review is based on various databases (PubMed, Science Direct, Wiley online library, Wanfang Data, Web of Science) through a search using the keyword "Gentiana" in the period of 1981-2019. Besides, other ethnopharmacological information was acquired from Chinese herbal classic books and Chinese pharmacopoeia 2015 edition. RESULTS: The plants from Gentiana genus have a long tradition of various medicinal uses in Europe and Asia. Phytochemical studies showed that the main bioactive components isolated from this genus includes iridoids xanthones and flavonoids. These compounds and extracts isolated from this genus show a wide range of protective activities including hepatic protection, gastrointestinal protection, cardiovascular protection, immunomodulation, joint protection, pulmonary protection, bone protection and reproductive protection. Molecular mechanism studies also indicated several potential therapeutic targets in the treatment of certain diseases by plants from this genus. Besides, natural products from this plant show no significant animal toxicity, cytotoxicity or genotoxicity. CONCLUSION: This review summarized the traditional medicinal uses, phytochemistry, pharmacology, toxicology and molecular mechanism of genus Gentiana, providing references and research tendency for plant-based drug development and further clinical studies.
Subject(s)
Drugs, Chinese Herbal/therapeutic use , Ethnopharmacology/methods , Gentiana , Phytochemicals/therapeutic use , Animals , Cardiovascular Agents/isolation & purification , Cardiovascular Agents/therapeutic use , Drugs, Chinese Herbal/isolation & purification , Ethnopharmacology/trends , Gastrointestinal Agents/isolation & purification , Gastrointestinal Agents/therapeutic use , Humans , Phytochemicals/isolation & purificationABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Scrophularia ningpoensis Hemsl. (known as Xuanshen) has been used in China for centuries as a traditional medicinal plant to treat numerous diseases including inflammation, hypertension, cancer, and diabetes. AIM OF REVIEW: In this review, we provide an update on the botany, pharmacology, phytochemistry, pharmacokinetics, traditional uses, and safety of S. ningpoensis to highlight future research needs and potential uses of this plant. MATERIALS AND METHODS: All information on S. ningpoensis was obtained from scientific databases including ScienceDirect, Springer, PubMed, Sci Finder, China Knowledge Resource Integrated Database from the China National Knowledge Infrastructure (CNKI), Google Scholar, and Baidu Scholar. Additional information was collected from Chinese herbal medicine books, Ph.D. dissertations, and M.Sc. Theses. Plant taxonomy was verified by "The Plant List" database (http://www.theplantlist.org). RESULTS: S. ningpoensis displays fever reducing, detoxifying, and nourishing 'Yin' effects in traditional Chinese medicine (TCM). More than 162 compounds have been identified and isolated from S. ningpoensis, including iridoids and iridoid glycosides, phenylpropanoid glycosides, organic acids, volatile oils, terpenoids, saccharides, flavonoids, sterols, and saponins. These compounds possess a diverse variety of pharmacological properties that affect the cardiovascular, hepatic, and nervous systems, and protect the body against inflammation, oxidation, and carcinogenesis. CONCLUSIONS: Modern pharmacological studies have confirmed that S. ningpoensis is a valuable Chinese medicinal herb with many pharmacological uses in the treatment of cardiovascular, diabetic, and liver diseases. Most of the S. ningpoensis activity may be attributed to iridoid glycosides and phenylpropanoid glycosides; however, detailed information on the molecular mechanisms, metabolic activity, toxicology, and structure-function relationships of active components is limited. Further comprehensive research to evaluate the medicinal properties of S. ningpoensis is needed.
Subject(s)
Drugs, Chinese Herbal/therapeutic use , Ethnopharmacology/methods , Medicine, Chinese Traditional/methods , Phytochemicals/therapeutic use , Scrophularia , Animals , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Cardiovascular Agents/isolation & purification , Cardiovascular Agents/pharmacology , Cardiovascular Agents/therapeutic use , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/pharmacology , Humans , Phytochemicals/isolation & purification , Phytochemicals/pharmacologyABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Coreopsis tinctoria Nutt. (family Asteraceae) is an important traditional medicine in North America, Europe, and Asia for quite a long historical period, which has received great attention due to its health-benefiting activities, including disinfection, treatment sexual infection, diarrhoea, acute and chronic dysentery, red-eye swelling as well as pain, heat, thirst, hypertension, palpitation, gastrointestinal discomfort, and loss of appetite. AIM OF THE REVIEW: The purpose of this review is to give an overview of the current phytochemistry and pharmacological activities of C. tinctoria, and reveals the correlation among its traditional uses, phytochemistry, pharmacological profile, and potential toxicity. MATERIALS AND METHODS: This review is based on published studies and books from electronic sources and library, including the online ethnobotanical database, ethnobotanical monographs, Scopus, SciFinder, Baidu Scholar, CNKI, and PubMed. These reports are related to the traditional uses, phytochemistry, pharmacology, and toxicology of C. tinctoria. RESULTS: Coreopsis tinctoria is traditionally used in diarrhoea, infection, and chronic metabolic diseases. From 1954 to now, more than 120 chemical constituents have been identified from C. tinctoria, such as flavonoids, polyacetylenes, polysaccharides, phenylpropanoids, and volatile oils. Flavonoids are the major bioactive components in C. tinctoria. Current research has shown that its extracts and compounds possess diverse biological and pharmacological activities such as antidiabetes, anti-cardiovascular diseases, antioxidant, anti-inflammatory, protective effects on organs, neuroprotective effects, antimicrobial, and antineoplastic. Studies in animal models, including acute toxicity, long-term toxicity, and genotoxicity have demonstrated that Snow Chrysanthemum is a non-toxic herb, especially for its water-soluble parts. CONCLUSIONS: Recent findings regarding the main phytochemical and pharmacological properties of C. tinctorial have confirmed its traditional uses in anti-infection and treatment of chronic metabolic disease and, more importantly, have revealed the plant as a valuable medicinal plant resource for the treatment of a wide range of diseases. The available reports indicated that most of the bioactivities in C. tinctorial could be attributed to flavonoids. However, higher quality studies on animals and humans studies are required to explore the efficacy and mechanism of action of C. tinctoria in future.
Subject(s)
Coreopsis , Ethnopharmacology/methods , Medicine, Traditional/methods , Phytochemicals/therapeutic use , Plant Extracts/therapeutic use , Animals , Cardiovascular Agents/isolation & purification , Cardiovascular Agents/pharmacology , Cardiovascular Agents/therapeutic use , Humans , Hypoglycemic Agents/isolation & purification , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Phytochemicals/isolation & purification , Phytochemicals/pharmacology , Plant Extracts/isolation & purification , Plant Extracts/pharmacologyABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: The plant Anchusa italica Retz. (Anchusa azurea Mill.) has been traditionally used in Uygur medicine for the treatment of cardiovascular and cerebrovascular diseases in China. Our previous study showed that total flavonoids from Anchusa italica Retz. (TFAI) exhibited potent cardioprotection in acute ischemia/reperfusion injured rats. AIM OF THE STUDY: This study was undertaken to investigate the effects of TFAI on chronic myocardial infarction (MI) in mice and the underlying mechanism. MATERIALS AND METHODS: Total flavonoids were extracted from the whole herb of Anchusa italica Retz. and were characterized using HPLC-MS analysis. The left anterior descending branch of the coronary artery was ligated to simulate MI injury in mice. After surgery, mice were orally fed with TFAI at the doses of 10, 30 and 50 mg/kg body weight/day for a total of four weeks. Cardiac function and infarct size were measured, and inflammatory mediators were detected. Hematoxylin and eosin (H&E) staining and Masson's trichrome staining were performed on heart sections. The apoptotic factors, such as Bax, Bcl-2 and cleaved caspase 3, as well as the key proteins in the PI3K/Akt/mTOR signaling pathway were examined by Western blot. RESULTS: The content of total flavonoids in TFAI was 56.2%. Four weeks following the MI surgery, TFAI enhanced the survival rate in post-MI mice. TFAI treatment at the doses of 30 and 50 mg/kg remarkably reduced infarct size and improved cardiac function as indicated by elevated EF and FS. Assay of the inflammatory factors showed that sera levels of TNF-α, IL-1ß and IL-6 were markedly decreased by TFAI treatment compared to the MI group. H&E staining and Masson's trichrome staining demonstrated that TFAI suppressed myocyte hypertrophy and cardiac fibrosis as indicated by the decreased cross-section area and collagen volume. Western blot analysis showed that cleaved caspase 3 and Bax/Bcl-2 were significantly downregulated following TFAI treatment. Furthermore, TFAI treatment significantly suppressed the activation of the PI3K/Akt/mTOR signaling pathway. CONCLUSIONS: Our data suggest that TFAI exerts a potent protective effect against chronic MI injury, and its beneficial effects on cardiac function and cardiac remodeling might be attributable, at least in part, to anti-inflammation and inhibition of the PI3K/Akt/mTOR signaling pathway.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Boraginaceae , Cardiovascular Agents/pharmacology , Flavonoids/pharmacology , Myocardial Infarction/drug therapy , Myocardium/pathology , Plant Extracts/pharmacology , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Animals , Anti-Inflammatory Agents/isolation & purification , Apoptosis/drug effects , Apoptosis Regulatory Proteins/metabolism , Boraginaceae/chemistry , Cardiovascular Agents/isolation & purification , Disease Models, Animal , Fibrosis , Flavonoids/isolation & purification , Inflammation Mediators/metabolism , Male , Mice, Inbred C57BL , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Myocardium/metabolism , Phosphatidylinositol 3-Kinase/metabolism , Plant Extracts/isolation & purification , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction , TOR Serine-Threonine KinasesABSTRACT
Quinolizidine alkaloids, a main form of alkaloids found in the genus Sophora, have been shown to have many pharmacological effects. This review aims to summarize the photochemical reports and biological activities of quinolizidine alkaloids in Sophora. The collected information suggested that a total of 99 quinolizidine alkaloids were isolated and detected from different parts of Sophora plants, represented by lupinine-type, cytisine-type, sparteine-type, and matrine-type. However, quality control needs to be monitored because it could provide basic information for the reasonable and efficient use of quinolizidine alkaloids as medicines and raw materials. The nonmedicinal parts may be promising to be used as a source of quinolizidine alkaloid raw materials and to reduce the waste of resources and environmental pollution. In addition, the diversity of chemical compounds based on the alkaloid scaffold to make a biological compound library needs to be extended, which may reduce toxicity and find new bioactivities of quinolizidine alkaloids. The bioactivities most reported are in the fields of antitumor activity along with the effects on the cardiovascular system. However, those studies rely on theoretical research, and novel drugs based on quinolizidine alkaloids are expected.
Subject(s)
Alkaloids/pharmacology , Plant Extracts/pharmacology , Quinolizidines/pharmacology , Sophora/chemistry , Alkaloids/isolation & purification , Alkaloids/standards , Alkaloids/therapeutic use , Analgesics/isolation & purification , Analgesics/pharmacology , Analgesics/therapeutic use , Anti-Infective Agents/isolation & purification , Anti-Infective Agents/pharmacology , Anti-Infective Agents/therapeutic use , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antimetabolites/isolation & purification , Antimetabolites/pharmacology , Antimetabolites/therapeutic use , Antineoplastic Agents/isolation & purification , Antineoplastic Agents/pharmacology , Antineoplastic Agents/standards , Antineoplastic Agents/therapeutic use , Cardiovascular Agents/isolation & purification , Cardiovascular Agents/pharmacology , Cardiovascular Agents/therapeutic use , Drug Development , Drug Discovery , Humans , Insecticides , Plant Extracts/isolation & purification , Plant Extracts/standards , Plant Extracts/therapeutic use , Quality Control , Quinolizidines/isolation & purification , Quinolizidines/standards , Quinolizidines/therapeutic useABSTRACT
Catechin, the name of which is derived from catechu of the extract of Acacia catechu L [...].
Subject(s)
Antioxidants/chemistry , Catechin/chemistry , Tea/chemistry , Anti-Infective Agents/chemistry , Anti-Infective Agents/isolation & purification , Anti-Obesity Agents/chemistry , Anti-Obesity Agents/isolation & purification , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/isolation & purification , Antioxidants/isolation & purification , Camellia sinensis/chemistry , Cardiovascular Agents/chemistry , Cardiovascular Agents/isolation & purification , Catechin/isolation & purification , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/isolation & purification , Isomerism , Neuroprotective Agents/chemistry , Neuroprotective Agents/isolation & purificationABSTRACT
INTRODUCTION: Terpenes are a class of secondary metabolites that can be found in a variety of animal and plants species. They are considered the most structurally diversified and abundant of all natural compounds. Several studies have shown the application of terpenes, such as carvacrol, linalool, and limonene in many pharmaceutical and medicinal fields, including cardiovascular disorders, the leading cause of death worldwide. AREAS COVERED: In this review, the authors outlined patents from the last 10 years relating to the therapeutic application of terpenes for the treatment and/or prevention of cardiovascular diseases found in different databases, emphasizing the possibility of these compounds becoming new drugs that may help to decrease the burden of these disorders. EXPERT OPINION: There has been a growing awareness over recent years of the therapeutic use of terpenes and their derivatives as new pharmaceutical products. Patents involving the use of terpenes have been especially important in the technological development of new strategies for the treatment of cardiovascular diseases by bringing new scientific knowledge into the pharmaceutical industry. Therefore, the development of biotechnologies using natural products should be encouraged in order to increase the variety of drugs available for the treatment of cardiovascular diseases.
Subject(s)
Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/drug therapy , Terpenes/therapeutic use , Animals , Biological Products/chemistry , Biological Products/isolation & purification , Biological Products/therapeutic use , Biotechnology/methods , Cardiovascular Agents/chemistry , Cardiovascular Agents/isolation & purification , Cardiovascular Diseases/physiopathology , Drug Development , Humans , Patents as Topic , Terpenes/chemistry , Terpenes/isolation & purificationABSTRACT
BACKGROUND AND OBJECTIVE: Panax Notoginseng Saponins (PNS) is a formula of Chinese medicine commonly used for treating ischemia myocardial in China. However, its mechanism of action is yet unclear. This study investigated the effect and the mechanism of PNS on myocardial ischemia-reperfusion injury (MIRI) through the hypoxia-inducible factor 1α (HIF-1α)/bcl-2/adenovirus E1B19kDa-interacting protein3 (BNIP3) pathway of autophagy. METHODS: We constructed a rat model of myocardial injury and compared among 4 groups (n = 10, each): the sham-operated group (Sham), the ischemia-reperfusion group (IR), the PNS low-dose group, and the PNS high-dose group were pretreated with PNS (30 and 60 mg/kg, respectively). Serum creatine kinase, malonaldehyde (MDA), lactate dehydrogenase, myocardial tissue superoxide dismutase, and reactive oxygen species were detected in rats with myocardial ischemia-reperfusion after the intervention of PNS. The rat myocardial tissue was examined using hematoxylin and eosin (H&E) staining, and the mitochondria of myocardial cells were observed using transmission electron microscopy. The expressions of microtubule-associated protein light chain 3 (LC3), HIF-1α, BNIP3, Beclin-1, and autophagy-related gene-5 (Atg5) in rat myocardial tissue were detected using Western blotting. RESULTS: The results showed that PNS was significantly protected against MIRI, as evidenced by the decreasing in the concentration of serum CK, MDA, lactate dehydrogenase, and myocardial tissue superoxide dismutase, reactive oxygen species, the attenuation of myocardial tissue histopathological changes and the mitochondrial damages of myocardial cells, and the increase of mitochondria autophagosome in myocardial cells. In addition, PNS significantly increased the expression of LC3 and the ratio of LC3II/LC3I in rat myocardial tissue. Moreover, PNS significantly increased the expression of HIF-1α, BNIP3, Atg5, and Beclin-1 in rat myocardial tissue. CONCLUSIONS: The protective effect of PNS on MIRI was mainly due to its ability to enhance the mitochondrial autophagy of myocardial tissue through the HIF-1α/BNIP3 pathway.
Subject(s)
Autophagy/drug effects , Cardiovascular Agents/pharmacology , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Membrane Proteins/metabolism , Mitochondrial Proteins/metabolism , Myocardial Infarction/prevention & control , Myocardial Reperfusion Injury/prevention & control , Myocytes, Cardiac/drug effects , Panax , Saponins/pharmacology , Animals , Autophagy-Related Protein 5/metabolism , Beclin-1/metabolism , Cardiovascular Agents/isolation & purification , Disease Models, Animal , Male , Microtubule-Associated Proteins/metabolism , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/ultrastructure , Panax/chemistry , Rats, Sprague-Dawley , Saponins/isolation & purification , Signal TransductionABSTRACT
OBJECTIVE: Saffron as a natural product has long been used to impede and treat different disorders including cardiovascular disease (CVDs). Stigma is the most principal part of saffron. Various compounds such as carotenoids and flavonoids are the essential components of saffron stigma. The health benefits of saffron have been shown in previous studies; however, there is a lack of comprehensive data on the mechanistic aspects of its cardiovascular-health properties. This current comprehensive review focuses on the medicinal applications of saffron, and then the new findings regarding its cardiovascular-health effects and various cellular and molecular mechanisms of action will be debated. METHODS: The literature search of MEDLINE, Embase, PubMed, Google Scholar and Cochrane Library was performed for all comparative studies since 2000-2018 with the limitations of the English language. RESULTS: The results provided new evidence about antioxidant, anti-inflammatory, anti- atherogenic, anti- apoptotic, anti- hypertensive, and hypolipidemic effects of saffron. Pharmacological effects of saffron are due to a number of ingredients contained within this spice, including safranal, crocetin and crocins. CONCLUSIONS: Our study concludes that saffron with wide range of usefulness in medicine may be the potent candidate in the process of new drug production for the treatment of CVDs.
Subject(s)
Cardiovascular Diseases/drug therapy , Crocus/chemistry , Plant Preparations/pharmacology , Animals , Cardiovascular Agents/isolation & purification , Cardiovascular Agents/pharmacology , Cardiovascular Diseases/physiopathology , Cardiovascular System/drug effects , Cardiovascular System/physiopathology , HumansABSTRACT
There is an increase in oxidative stress and apoptosis signaling during the transition from hypertrophy to right ventricular (RV) failure caused by pulmonary arterial hypertension (PAH) induced by monocrotaline (MCT). In this study, it was evaluated the action of copaiba oil on the modulation of proteins involved in RV apoptosis signaling in rats with PAH. Male Wistar rats (±170 g, n = 7/group) were divided into 4 groups: control, MCT, copaiba oil, and MCT + copaiba oil. PAH was induced by MCT (60 mg/kg intraperitoneally) and, 7 days later, treatment with copaiba oil (400 mg/kg by gavage) was given for 14 days. Echocardiographic and hemodynamic measurements were performed, and the RV was collected for morphometric evaluations, oxidative stress, apoptosis, and cell survival signaling, and eNOS protein expression. Copaiba oil reduced RV hypertrophy (24%), improved RV systolic function, and reduced RV end-diastolic pressure, increased total sulfhydryl levels and eNOS protein expression, reduced lipid and protein oxidation, and the expression of proteins involved in apoptosis signaling in the RV of MCT + copaiba oil as compared to MCT group. In conclusion, copaiba oil reduced oxidative stress, and apoptosis signaling in RV of rats with PAH, which may be associated with an improvement in cardiac function caused by this compound.
Subject(s)
Apoptosis/drug effects , Cardiovascular Agents/pharmacology , Fabaceae , Hypertension, Pulmonary/drug therapy , Hypertrophy, Right Ventricular/prevention & control , Monocrotaline , Myocardium , Plant Oils/pharmacology , Ventricular Dysfunction, Right/prevention & control , Ventricular Function, Right/drug effects , Ventricular Remodeling/drug effects , Animals , Cardiovascular Agents/isolation & purification , Disease Models, Animal , Fabaceae/chemistry , Hypertension, Pulmonary/chemically induced , Hypertension, Pulmonary/metabolism , Hypertension, Pulmonary/pathology , Hypertrophy, Right Ventricular/chemically induced , Hypertrophy, Right Ventricular/metabolism , Hypertrophy, Right Ventricular/pathology , JNK Mitogen-Activated Protein Kinases/metabolism , Male , Myocardium/metabolism , Myocardium/pathology , Nitric Oxide Synthase Type III/metabolism , Oxidative Stress/drug effects , Plant Oils/isolation & purification , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats, Wistar , Signal Transduction/drug effects , Ventricular Dysfunction, Right/chemically induced , Ventricular Dysfunction, Right/metabolism , Ventricular Dysfunction, Right/pathology , bcl-2-Associated X Protein/metabolismABSTRACT
CONTEXT: Cardiovascular disease (CVD) is the number one cause of death globally, responsible for over 17 million (31%) deaths in the world. Novel pharmacological interventions may be needed given the high prevalence of CVD. OBJECTIVE: In this study, we aimed to find potential new sources of cardiovascular (CV) drugs from phylogenetic and pharmacological analyses of plant species that have experimental and traditional CV applications in the literature. MATERIALS AND METHODS: We reconstructed the molecular phylogeny of these plant species and mapped their pharmacological mechanisms of action on the phylogeny. RESULTS: Out of 139 plant species in 71 plant families, seven plant families with 45 species emerged as phylogenetically important exhibiting common CV mechanisms of action within the family, as would be expected given their common ancestry: Apiaceae, Brassicaceae, Fabaceae, Lamiaceae, Malvaceae, Rosaceae and Zingiberaceae. Apiaceae and Brassicaceae promoted diuresis and hypotension; Fabaceae and Lamiaceae had anticoagulant/thrombolytic effects; Apiaceae and Zingiberaceae were calcium channel blockers. Moreover, Apiaceae, Lamiaceae, Malvaceae, Rosaceae and Zingiberaceae species were found to possess anti-atherosclerotic properties. DISCUSSION AND CONCLUSIONS: The phylogeny identified certain plant families with disproportionately more species, highlighting their importance as sources of natural products for CV drug discovery. Though there were some species that did not show the same mechanism within the family, the phylogeny predicts that these species may contain undiscovered phytochemistry, and potentially, the same bioactivity. Evolutionary pharmacology, as applied here, may guide and expedite our efforts in discovering sources of new CV drugs.
Subject(s)
Cardiovascular Agents/isolation & purification , Drug Discovery/methods , Ethnobotany/methods , Phylogeny , Plants, Medicinal/genetics , Cardiovascular Agents/chemistry , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/drug therapy , Drug Discovery/trends , Ethnobotany/trends , Forecasting , Humans , Plants, Medicinal/classificationABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: The compound epigallocatechin-3-gallate (EGCG), the major polyphenolic compound present in green tea [Camellia sinensis (Theaceae], has shown numerous cardiovascular health promoting activity through modulating various pathways. However, molecular understanding of the cardiovascular protective role of EGCG has not been reported. AIM OF THE REVIEW: This review aims to compile the preclinical and clinical studies that had been done on EGCG to investigate its protective effect on cardiovascular and metabolic diseases in order to provide a systematic guidance for future research. MATERIALS AND METHODS: Research papers related to EGCG were obtained from the major scientific databases, for example, Science direct, PubMed, NCBI, Springer and Google scholar, from 1995 to 2017. RESULTS: EGCG was found to exhibit a wide range of therapeutic properties including anti-atherosclerosis, anti-cardiac hypertrophy, anti-myocardial infarction, anti-diabetes, anti-inflammatory and antioxidant. These therapeutic effects are mainly associated with the inhibition of LDL cholesterol (anti-atherosclerosis), inhibition of NF-κB (anti-cardiac hypertrophy), inhibition of MPO activity (anti-myocardial infarction), reduction in plasma glucose and glycated haemoglobin level (anti-diabetes), reduction of inflammatory markers (anti-inflammatory) and the inhibition of ROS generation (antioxidant). CONCLUSION: EGCG shows different biological activities and in this review, a compilation of how this bioactive molecule plays its role in treating cardiovascular and metabolic diseases was discussed.
Subject(s)
Cardiovascular Diseases/drug therapy , Catechin/analogs & derivatives , Metabolic Diseases/drug therapy , Animals , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/pharmacology , Camellia sinensis/chemistry , Cardiovascular Agents/isolation & purification , Cardiovascular Agents/pharmacology , Cardiovascular Diseases/physiopathology , Catechin/isolation & purification , Catechin/pharmacology , Humans , Metabolic Diseases/physiopathology , Tea/chemistryABSTRACT
Heart failure is a major medical and economic burden throughout the world. Although various treatment options are available to treat heart failure, death rates in both men and women remain high. Potential adjunctive therapies may lie with use of herbal medications, many of which possess potent pharmacological properties. Among the most widely studied is ginseng, a member of the genus Panax that is grown in many parts of the world and that has been used as a medical treatment for a variety of conditions for thousands of years, particularly in Asian societies. There are a number of ginseng species, each possessing distinct pharmacological effects due primarily to differences in their bioactive components including saponin ginsenosides and polysaccharides. While experimental evidence for salutary effects of ginseng on heart failure is robust, clinical evidence is less so, primarily due to a paucity of large-scale well-controlled clinical trials. However, there is evidence from small trials that ginseng-containing Chinese medications such as Shenmai can offer benefit when administered as adjunctive therapy to heart failure patients. Substantial additional studies are required, particularly in the clinical arena, to provide evidence for a favourable effect of ginseng in heart failure patients.
Subject(s)
Cardiomegaly/drug therapy , Cardiovascular Agents/therapeutic use , Ginsenosides/therapeutic use , Heart Failure/drug therapy , Panax/chemistry , Plant Extracts/therapeutic use , Animals , Cardiomegaly/diagnosis , Cardiomegaly/physiopathology , Cardiovascular Agents/adverse effects , Cardiovascular Agents/isolation & purification , Cells, Cultured , Clinical Trials as Topic , Disease Models, Animal , Ginsenosides/adverse effects , Ginsenosides/isolation & purification , Heart Failure/diagnosis , Heart Failure/physiopathology , Humans , Phytotherapy , Plant Extracts/adverse effects , Plant Extracts/isolation & purification , Plants, Medicinal , Treatment OutcomeABSTRACT
In the present study, three new triterpenoids, 23-hydroxyurs-12, 18-dien-28-oic acid 3ß-O-α-L-arabinopyranoside (1), 23-hydroxyurs-12, 18-dien-28-oic acid 3ß-O-ß-D-glucuronopyranoside-6-O-methyl ester (2), and urs-12, 18-dien-28-oic acid 3ß-O-ß-D-glucuronopyranoside-6-O-methyl ester (3), and a known triterpenoid, 3ß-hydroxy-urs-2, 18-dien-28-oic acid (4, randialic acid B), were isolated from the aerial parts of Ilex cornuta. Their structures were identified by the spectroscopic analyses (IR, ESI-MS, HR-ESI-MS, and 1D and 2D NMR) and chemical reactions. Compound 4 showed significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury. Compounds 1-4 did not show any significant DPPH radical scavenging activity.
Subject(s)
Ilex/chemistry , Myocardium/pathology , Plant Extracts/pharmacology , Triterpenes/pharmacology , Animals , Biphenyl Compounds/metabolism , Cardiovascular Agents/chemistry , Cardiovascular Agents/isolation & purification , Cardiovascular Agents/pharmacology , Hydrogen Peroxide/metabolism , Molecular Structure , Myocardium/cytology , Myocytes, Cardiac/drug effects , Picrates/metabolism , Plant Components, Aerial/chemistry , Plant Extracts/chemistry , Rats , Triterpenes/chemistry , Triterpenes/isolation & purificationABSTRACT
BACKGROUND AND AIMS: Apple polyphenol contains abundant procyanidins, which have been associated with an anti-atherosclerosis and cholesterol-lowering effect. The aim of this study was to investigate whether apple procyanidins (APCs) feature therapeutic efficacy in terms of regressing atherosclerosis and whether this efficacy is due to mechanisms other than a cholesterol-lowering effect. METHODS: After eight weeks on an atherogenic diet, rabbits were given a normal diet for another eight weeks to normalize the increased serum lipids level. The rabbits in the baseline group were sacrificed at this stage. The control group was subsequently fed a normal diet for eight weeks, while the APCs group was administrated 50 mg/kg/day of APCs in addition to the normal diet. Serum lipids and aortic intimal-medial thickness (IMT) were serially examined, and the resected aorta was examined histologically and through molecular biology. RESULTS: Aortic IMT on ultrasonography and the lipid accumulation area examined using Sudan IV staining were significantly reduced in the APCs group as compared to the control group. Serum lipid profiles were not different between the groups. Immunohistochemistry showed significantly decreased staining of an oxidative stress marker and significantly increased staining of ATP-binding cassette subfamily A member 1 (ABCA1) in the APCs group. Western blotting and RT-PCR also showed increased expression of ABCA1 mRNA and its protein in the APCs group. CONCLUSIONS: This study revealed that APCs administration causes a regression of atherosclerosis. APCs might hold promise as an anti-atherosclerotic agent.
Subject(s)
ATP Binding Cassette Transporter 1/agonists , Aorta/drug effects , Aortic Diseases/prevention & control , Atherosclerosis/prevention & control , Biflavonoids/pharmacology , Cardiovascular Agents/pharmacology , Catechin/pharmacology , Fruit/chemistry , Malus/chemistry , Proanthocyanidins/pharmacology , ATP Binding Cassette Transporter 1/genetics , ATP Binding Cassette Transporter 1/metabolism , Animals , Aorta/metabolism , Aorta/pathology , Aortic Diseases/metabolism , Aortic Diseases/pathology , Atherosclerosis/metabolism , Atherosclerosis/pathology , Biflavonoids/isolation & purification , Cardiovascular Agents/isolation & purification , Catechin/isolation & purification , Cholesterol/blood , Disease Models, Animal , Lipoproteins, LDL/blood , Male , Oxidative Stress/drug effects , Phytotherapy , Plants, Medicinal , Plaque, Atherosclerotic , Proanthocyanidins/isolation & purification , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reactive Oxygen Species/blood , Scavenger Receptors, Class E/metabolism , Time Factors , Up-RegulationABSTRACT
ETHNOBOTANICAL RELEVANCE: Pogostemon elsholtzioides Benth. (Lamiaceae) is an aromatic shrub, endemic to eastern Himalaya region. The leaves are used for treating goiter and high blood pressure (BP) by indigenous people in Arunachal Pradesh, India. Young leaves are used as vegetable and leaf decoction is also used for cough, cold and headache by some indigenous communities in Northeast India. AIM OF THE STUDY: This species is used for treating hypertension and the genus Pogostemon is rich in essential oil. Therefore, the present study was aimed at investigation of the chemical constituents, vasorelaxant and cardiovascular effects of the essential oil of P. elsholtzioides. MATERIALS AND METHODS: P. elsholtzioides was collected from Pasighat, Arunachal Pradesh, India and essential oil was extracted from shade dried leaves. Essential oil was analyzed by GC-FID and GC-MS and the volatile constituents were identified. Vasorelaxant and cardiovascular properties of the essential oil were studied against phenylephrine induced contraction in isolated endothelium intact aortic preparations and by measuring systolic and diastolic BP, mean arterial pressure (MAP) and heart rate (HR) after carotid artery cannulation in Wistar rats. RESULTS: The essential oil was rich in sesquiterpenes and curzerene, benzophenone, α-cadinol and germacrone were major constituents. The essential oil exhibited significant vasodilation effect in phenylephrine induced contracted aortic rings. Vasorelaxant effect of the essential oil was also observed both in the presence and absence of Nitro-L-arginine methyl ester against phenylephrine-contracted aortic rings. It also induced reduction of systolic and diastolic BP, MAP and HR. CONCLUSIONS: Essential oil of P. elsholtzioides exhibited significant vasorelaxant effect against endothelium intact aortic preparation mediated through nitric oxide dependent pathway and also reduced BP. However, further study is needed to screen the role of calcium ions in both intracellular and extracellular pathway.